In addition, DRs, including DR4 and DR5 for TRAIL, were overexpressed in tumor tissues from CRC patients (Figure 1(A)), indicating the potential of TRAIL for clinical therapy of CRC. The gene discussed is TNFRSF10A; the disease is colorectal carcinoma.